TABLE 1.
Baseline characteristics patients with resectable gastric cancer by facility type
| Variable | All patients n = 284 (%) | SNH n = 64 (36) | TRC n = 112 (64) | p value |
|---|---|---|---|---|
| Demographic features | ||||
| Age at diagnosis (median, IQR) | 63 (54–72) | 58 (51–66) | 65 (57–75) | <0.01 |
| Gender | 0.43 | |||
| Female | 113 (40) | 48 (37) | 65 (42) | |
| Male | 171 (60) | 82 (63) | 89 (58) | |
| Race | <0.01 | |||
| White | 152 (57) | 52 (44) | 100 (67) | |
| Black | 72 (27) | 39 (33) | 33 (22) | |
| Asian | 43 (16) | 27 (23) | 16 (11) | |
| Ethnicity | 0.02 | |||
| Non-Hispanic | 207 (73) | 84 (65) | 123 (80) | |
| Hispanic | 75 (27) | 45 (35) | 30 (20) | |
| Insurance status | <0.01 | |||
| No insurance | 55 (20) | 54 (41) | 1 (1) | |
| Insurance | 227 (80) | 76 (59) | 151 (99) | |
| Functional status | <0.01 | |||
| Independent | 248 (89) | 125 (97) | 123 (83) | |
| Partially/totally dependent | 30 (11) | 4 (3) | 26 (17) | |
| Location of diagnosis | <0.01 | |||
| ED | 95 (34) | 71 (55) | 24 (16) | |
| Primary care clinic | 169 (61) | 52 (40) | 117 (80) | |
| Incidental | 13 (5) | 7 (5) | 6 (4) | |
| Median follow-up (median, IQR) | 15 (6–30) | 17 (6–33) | 14 (5–27) | 0.10 |
| Clinicopathologic features | ||||
| Bleeding symptoms | 0.23 | |||
| No | 205 (96) | 63 (93) | 142 (97) | |
| Yes | 9 (4) | 5 (7) | 4 (3) | |
| Obstructive symptoms | 0.27 | |||
| No | 143 (51) | 61 (47) | 82 (54) | |
| Yes | 138 (49) | 69 (53) | 69 (46) | |
| Clinical stage | 0.20 | |||
| I | 77 (38) | 37 (32) | 40 (44) | |
| II | 71 (35) | 43 (38) | 28 (31) | |
| III | 57 (27) | 35 (30) | 22 (24) | |
| Location of tumor | 0.03 | |||
| GE junction/cardia | 77 (28) | 27 (21) | 50 (34) | |
| Body/antrum | 197 (72) | 99 (79) | 98 (66) | |
| Pathologic stage | 0.45 | |||
| 0 | 11 (4) | 2 (2) | 9 (6) | |
| I | 78 (29) | 38 (31) | 40 (28) | |
| II | 83 (31) | 39 (31) | 44 (31) | |
| III | 60 (22) | 28 (23) | 32 (22) | |
| IV | 36 (14) | 17 (13) | 19 (13) | |
| Any postoperative complication | 0.95 | |||
| No | 95 (66) | 41 (66) | 54 (67) | |
| Yes | 48 (34) | 21 (34) | 27 (33) | |
| Treatment features | ||||
| Neoadjuvant therapy | 0.33 | |||
| No | 196 (69) | 94 (72) | 102 (66) | |
| Yes | 88 (31) | 36 (28) | 52 (34) | |
| Neoadjuvant chemotherapy | 0.27 | |||
| No | 88 (50) | 28 (44) | 60 (54) | |
| Yes | 88 (50) | 36 (56) | 52 (46) | |
| Perioperative therapy | 0.47 | |||
| No | 120 (68) | 41 (64) | 79 (71) | |
| Yes | 56 (32) | 23 (36) | 33 (29) | |
| Adjuvant therapy | 0.20 | |||
| No | 133 (47) | 55 (43) | 8 (51) | |
| Yes | 149 (53) | 74 (57) | 75 (49) | |
| Adjuvant chemotherapy | 0.50 | |||
| No | 74 (37) | 34 (34) | 40 (40) | |
| Yes | 127 (63) | 66 (66) | 61 (60) | |
| Adjuvant radiation | <0.01 | |||
| No | 143 (84) | 55 (73) | 88 (92) | |
| Yes | 28 (16) | 20 (27) | 8 (8) | |
| Adjuvant chemoradiation | 0.86 | |||
| No | 115 (80) | 35 (80) | 80 (81) | |
| Yes | 28 (20) | 9 (20) | 19 (19) |
Abbreviations: ED, emergency department; GE, gastroesophageal; IQR, interquartile range.